Invalid Symbol

Stock Research for IPXL

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


IPXL Stock Chart & Research Data

The IPXL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPXL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


IPXL Due diligence Resources & Stock Charts

The IPXL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IPXL Detailed Price Forecast - CNN Money CNN View IPXL Detailed Summary - Google Finance
Yahoo View IPXL Detailed Summary - Yahoo! Finance Zacks View IPXL Stock Research & Analysis -

Stock Analysis

TradeIdeas View IPXL Trends & Analysis - Trade-Ideas Barrons View IPXL Major Holders - Barrons
NASDAQ View IPXL Call Transcripts - NASDAQ Seeking View IPXL Breaking News & Analysis - Seeking Alpha
Spotlight View IPXL Annual Report - OTC Report View IPXL OTC Short Report -
TradeKing View IPXL Fundamentals - TradeKing Charts View IPXL SEC Filings - Bar Chart
WSJ View Historical Prices for IPXL - The WSJ Morningstar View Performance/Total Return for IPXL - Morningstar
MarketWatch View the Analyst Estimates for IPXL - MarketWatch CNBC View the Earnings History for IPXL - CNBC
StockMarketWatch View the IPXL Earnings - StockMarketWatch MacroAxis View IPXL Buy or Sell Recommendations - MacroAxis
Bullish View the IPXL Bullish Patterns - American Bulls Short Pains View IPXL Short Pain Metrics -

Social Media Mentions

StockTwits View IPXL Stock Mentions - StockTwits PennyStocks View IPXL Stock Mentions - PennyStockTweets
Twitter View IPXL Stock Mentions - Twitter Invest Hub View IPXL Investment Forum News - Investor Hub
Yahoo View IPXL Stock Mentions - Yahoo! Message Board Seeking Alpha View IPXL Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for IPXL - Insider Cow View Insider Transactions for IPXL - Insider Cow
CNBC View IPXL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IPXL - OTC Markets
Yahoo View Insider Transactions for IPXL - Yahoo! Finance NASDAQ View Institutional Holdings for IPXL - NASDAQ

Stock Charts

FinViz View IPXL Stock Insight & Charts - StockCharts View IPXL Investment Charts -
BarChart View IPXL Stock Overview & Charts - BarChart Trading View View IPXL User Generated Charts - Trading View

Latest Financial News for IPXL

Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
Posted on Tuesday February 20, 2018

Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.

Lee Ainslie Boosts 2 Health Care Positions
Posted on Monday February 12, 2018

The guru added to his Envision Healthcare and Impax Laboratories holdings

Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations
Posted on Tuesday February 06, 2018

BRIDGEWATER, N.J., Feb. 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL), today announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with Impax. "We are pleased that Andy has joined Amneal and will be leading our commercial organization," said Chirag Patel, Co-CEO and chairman, Amneal Pharmaceuticals. Mr. Boyer will work closely with Chirag and Chintu Patel, Amneal's current Co-CEOs, and Rob Stewart, President of Amneal and the future CEO of the new Amneal, to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.

Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®
Posted on Monday February 05, 2018

BRIDGEWATER, N.J. , Feb. 5, 2018 /PRNewswire/ --  Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP (CII) in 18, 27, 36, and 54 mg strengths. Amneal's methylphenidate ...

As Impax Laboratories INC (IPXL) Valuation Rose, Fosun International LTD Upped ...
BZ Weekly - 1 hour ago
Investors sentiment increased to 1.75 in Q3 2017. Its up 0.85, from 0.9 in 2017Q2. It improved, as 14 investors sold IPXL shares while 39 reduced holdings.
As Impax Laboratories INC (IPXL) Share Price Rose, Fosun International LTD ... - Frisco Fastball
Impax Laboratories Inc (IPXL) Position Boosted by TCW Group Inc. - Dispatch Tribunal

Impax Laboratories Inc. (IPXL) Soars 5.82% on January 25 - Jan 25, 2018
Impax Laboratories Inc. (IPXL) had a good day on the market for Thursday January 25 as shares jumped 5.82% to close at $20.90.
Wall Street Analyst Actions To Watch: Impax Laboratories, Inc. (IPXL), Oclaro ... - Post Analyst
Comparing Top Moving Stocks Apple Inc. (AAPL), Impax Laboratories, Inc. (IPXL) - StockNewsGazette

News Roundup: Impax Laboratories Inc. (NASDAQ:IPXL), Northern Oil and Gas, Inc ...
The Oracle Examiner - 7 hours ago
Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery ...
$0.12 EPS Expected for Impax Laboratories, Inc. (IPXL) - BZ Weekly
EPS for Impax Laboratories, Inc. (IPXL) Expected At $0.12; Immune Design Corp ... - Hill Country Times

Impax Labs Inc (IPXL): Stock Overview
ExpertGazette - 9 hours ago
Impax Labs Inc (NASDAQ:IPXL) has grabbed attention from the analysts, when it saw a value increase of 1.03% or 0.2 points in the last trading session to close at $19.6.

Enter a stock symbol to view the stock details.